Short Wave cover image

FDA Approves Aducanumab — A Controversial Drug For Alzheimer's

Short Wave

00:00

The Approval of Aducanumab: A New Hope or Controversial Gamble in Alzheimer's Treatment

This chapter explores the FDA's approval of the Alzheimer’s drug aducanumab, detailing its controversy and implications for patients and healthcare providers. It examines the scientific foundations of amyloid drugs, the history of Alzheimer’s treatment failures, and the mixed sentiments of optimism and skepticism among developers.

Play episode from 01:43
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app